

DISCLAIMER

Publication of

Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

NPS EX. 2144 CFAD v. NPS IPR2015-00990



Publication contributors

Published on February 23, 2010 by Merck KGaA,

Corporate Communications

Frankfurter Strasse 250, 64293 Darmstadt, Germany Tel.: +49 (0) 6151-72 0, fax: +49 (0) 6151-72 5577

E-mail: corpcom@merck.de Website: www.merck.de

Concept, design and typesetting: XEO GmbH, Düsseldorf, Germany

Photographs: Pages 6, 10 and 11: Catrin Moritz, Essen; Pages 1, 2, 4, 35, 51, 57, and 63: Reinhard Koslowski, Düsseldorf Printing: Franz Kuthal GmbH & Co. KG, Mainaschaff, Germany

Paper: FSC-certified "heaven 42" by Scheufelen







COMPANY

- 2 The history of Merck
- 3 Becoming a global, publicly listed company
- 4 Merck today
- 4 The future

TO OUR SHAREHOLDERS

- 6 Letter from Karl-Ludwig Kley
- 10 Executive Board

MANAGEMENT REPORT

- 13 Overall economic situation
- 15 Financial position and results of operations
- 26 Responsibility
- 29 Merck shares
- 34 Pharmaceuticals | Merck Serono
- 50 Pharmaceuticals | Consumer Health Care
- 56 Chemicals | Liquid Crystals
- 62 Chemicals | Performance & Life Science Chemicals
- 68 Corporate and Other
- 70 Risk report
- 75 Report on expected developments
- 80 Subsequent events

CORPORATE GOVERNANCE

- 82 Statement on corporate governance
- 93 Report of the Supervisory Board

CONSOLIDATED FINANCIAL STATEMENTS

- 96 Income Statement
- 97 Balance Sheet
- 98 Segment Reporting
- 100 Cash Flow Statement
- 101 Free Cash Flow
- 101 Statement of Comprehensive Income
- 101 Statement of Changes in Net Equity including Minority Interest
- 103 Notes


FURTHER INFORMATION

- 161 Responsibility Statement
- 162 Auditor's Report
- 164 Glossary
- 168 Financial calendar for 2010
- 168 More information


Publication contributors

MERCK AT A GLANCE

Key figures for 2009					
€ million	Pharma- ceuticals	Chemicals	Corporate and Other	Total	Change in %
Total revenues	5,812	1,935	0	7,747	2.1
Gross margin	4,805	913	0	5,718	0.6
Research and development	1,203	142		1,345	8.9
Operating result	403	324	-78	649	-43
Exceptional items	-40	12	_	-28	_
Earnings before interest and tax (EBIT)	363	336	-78	621	-15
EBIT before depreciation and amortization (EBITDA)	1,221	479	-75	1,625	-17
Return on sales in % (ROS: operating result/total revenues)	6.9	16.8		8.4	
Free cash flow	913	410	-511	812	85
Underlying free cash flow	916	432	-496	852	42
Underlying free cash flow on revenues (FCR) in %	15.8	22.3		11.0	



■ Chemicals ■ Pharmaceuticals




Operating result by business sector

400

2005 2006 2007 2008 2009

■ Chemicals ■ Pharmaceuticals ■ Corporate and Other









ABOUT MERCK

At Merck, the Pharmaceuticals and Chemicals businesses are under one roof. We are convinced that in both sectors, the market will reward successful research and technological advances with attractive margins. We focus on specialty businesses within both Chemicals and Pharmaceuticals. We are not interested in engaging in commodity markets or businesses where competition is dictated by price alone.

THE HISTORY OF MERCK

It all started with a pharmacy in 1668. The Angel Pharmacy, which is still owned by members of the Merck family today, is where Merck originated. Like his contemporaries, the pharmacist Friedrich Jacob Merck prepared all medicinal substances himself. At that time, the "art of pharmacy" was still a manual craft.

In 1816 – several generations of pharmacists later – Emanuel Merck took over his father's pharmacy and initiated the move from a manual craft to industrial production in 1827. In his laboratory, he succeeded in extracting alkaloids, a class of highly effective plant constituents whose medicinal effect attracted interest from the scientific community. By 1860, the company already offered more than 800 organic and inorganic substances for sale, including many still used in laboratories today.

The roots of the Liquid Crystals business – one of the outstanding Merck success stories – date back to 1904. For decades, liquid crystals remained a laboratory oddity, and their sale was handled by the Laboratory business.

Serono, which was acquired by Merck in 2007, also started out by extracting active substances. In 1906, Cesare Serono founded the "Istituto Farmacologico Serono" in Rome and developed a new method of extracting lecithin from egg yolk. In 1949, the company discovered a way to successfully isolate pure gonadotropin from urine. Gonadotropin plays an important role in reproduction. The production of recombinant gonadotropin transformed Serono into a biotechnology company.

In the early 19th century, the scientific community took particular interest in the extraction of alkaloids, highly effective plant constituents with a medicinal action. Quinine, depicted here, was one such alkaloid.





DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

